ADCT 901
Alternative Names: 3A4 PL1601; ADCT-901Latest Information Update: 11 Jan 2024
At a glance
- Originator ADC Therapeutics
- Developer ADC Therapeutics; Overland ADCT BioPharma
- Class Antibodies; Antineoplastics; Benzodiazepines; Drug conjugates; Immunoconjugates; Immunotherapies; Immunotoxins; Monoclonal antibodies; Pyrroles
- Mechanism of Action DNA cross linking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 04 Jan 2024 Discontinued - Phase-I for Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in Spain (IV)
- 04 Jan 2024 Discontinued - Phase-I for Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (IV)
- 04 Jan 2024 Discontinued - Preclinical for Solid tumours in China (IV)